| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8725086 | Clinical Gastroenterology and Hepatology | 2018 | 35 Pages |
Abstract
In an analysis of data from 2 phase 3 clinical trials of patients with chronic HCV infection of any genotype, we found the combination of sofosbuvir, velpatasvir, with or without voxilaprevir, to increase PRO scores compared with placebo. These findings indicate the comprehensive benefit of these regimens during treatment and after SVR.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Zobair M. Younossi, Maria Stepanova, Stuart Gordon, Stefan Zeuzem, Michael P. Mann, Ira Jacobson, Marc Bourliere, Curtis Cooper, Steven Flamm, K. Rajender Reddy, Kris Kowdley, Issah Younossi, Sharon Hunt,